Cellebrite DI (NASDAQ:CLBT) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Cellebrite DI (NASDAQ:CLBT) issued its quarterly earnings results on Wednesday. The company reported $0.14 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05, Briefing.com reports. Cellebrite DI had a negative return on equity of 748.06% and a negative net margin of 82.28%. The business had revenue of $106.90 million during the quarter, compared to the consensus estimate of $102.06 million. During the same period in the previous year, the business earned $0.09 EPS. The business’s quarterly revenue was up 27.0% on a year-over-year basis. Cellebrite DI updated its FY 2024 guidance to EPS and its Q4 2024 guidance to EPS.

Cellebrite DI Stock Performance

Cellebrite DI stock traded down $0.18 during mid-day trading on Friday, reaching $18.61. The company’s stock had a trading volume of 1,434,023 shares, compared to its average volume of 1,148,436. Cellebrite DI has a 12-month low of $7.22 and a 12-month high of $21.00. The company has a market capitalization of $3.83 billion, a P/E ratio of -12.01, a PEG ratio of 2.63 and a beta of 1.50. The firm’s fifty day moving average price is $17.62 and its two-hundred day moving average price is $14.29.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on CLBT. Needham & Company LLC raised their price target on shares of Cellebrite DI from $17.00 to $21.00 and gave the stock a “buy” rating in a report on Thursday. TD Cowen upped their target price on shares of Cellebrite DI from $20.00 to $23.00 and gave the company a “buy” rating in a report on Monday, September 23rd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Cellebrite DI from $15.00 to $18.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Bank of America upped their price target on shares of Cellebrite DI from $13.00 to $17.00 and gave the company a “buy” rating in a report on Friday, August 16th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cellebrite DI from $21.00 to $22.00 and gave the stock an “overweight” rating in a research note on Thursday. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $20.29.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.